| 3.95 0.27 (7.34%) | 02-19 14:01 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.66 |
1-year : | 5.44 |
| Resists | First : | 3.99 |
Second : | 4.66 |
| Pivot price | 3.44 |
|||
| Supports | First : | 3.16 |
Second : | 2.66 |
| MAs | MA(5) : | 3.65 |
MA(20) : | 3.32 |
| MA(100) : | 2.72 |
MA(250) : | 2.25 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 81.3 |
D(3) : | 78.9 |
| RSI | RSI(14): 66.3 |
|||
| 52-week | High : | 4.98 | Low : | 1.04 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IBIO ] has closed below upper band by 8.6%. Bollinger Bands are 55% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.81 - 3.83 | 3.83 - 3.85 |
| Low: | 3.34 - 3.36 | 3.36 - 3.39 |
| Close: | 3.64 - 3.68 | 3.68 - 3.72 |
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
Mon, 17 Feb 2025
Is Ibio, Inc. (IBIO) Among Stocks Insiders Are Buying This Year? - Yahoo Finance
Mon, 17 Feb 2025
10 Stocks Insiders Are Buying This Year - Insider Monkey
Wed, 12 Feb 2025
Ibio Inc Faces Financial Risk from Potential Stockholder Equity Dilution and Capital Raising Challenges - TipRanks
Mon, 10 Feb 2025
iBio Inc. stock falls Monday, underperforms market - MarketWatch
Mon, 10 Feb 2025
iBio, Inc. Reports Second Quarter Fiscal 2025 Financial Results and Corporate Updates on Advancements in Cardiometabolic Therapeutics - Nasdaq
Mon, 10 Feb 2025
IBIO's Strategic Pivot: AI-Powered Antibody Discovery Shows Promise Despite Q2 Losses - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 6.84e+006 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 76 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.725e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -36 % |
| Return on Assets (ttm) | 380 % |
| Return on Equity (ttm) | -24.1 % |
| Qtrly Rev. Growth | 50000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -7.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.57 |
| Dividend | 0 |
| Forward Dividend | 89920 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|